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Abstract
 
Mature B cells can alter their antibody repertoires by several mechanisms, including immuno-
globulin heavy chain variable region (V
 
H
 
) replacement. This process changes the antigen com-
bining site by replacing a portion of the original V
 
H
 
/diversity/heavy chain joining region (V
 
H-
 
DJ
 
H
 
) rearrangement with a corresponding portion of a new V
 
H
 
 segment. This exchange can
involve cryptic heptamer-like sequences embedded in the coding regions of V
 
H
 
 genes.
 
While studying the B lymphocytes that expand in the synovial tissues of patients with rheu-
 
matoid arthritis (RA), clones with V
 
H
 
DJ
 
H
 
 variants that were apparently generated by V
 
H
 
 re-
 
placement were identified with surprising frequency (
 
z
 
8%). Examples of multiple independent
V
 
H
 
 replacement events occurring in distinct progeny clones were also identified. These second-
 
ary V
 
H
 
 rearrangements were documented at both the cDNA and genomic DNA levels and
involved several heptamer-like sequences at four distinct locations within V
 
H
 
 (three sites in
 
framework region 3 and one in complementarity determining region 2). The identification of
blunt-ended double-stranded DNA breaks at the embedded heptamers and the demonstration of
recombinase activating gene (RAG) expression suggested that these rearrangements could occur
in the synovial tissues, presumably in pseudo-germinal centers, and that they could be mediated
 
by RAG in a recognition signal sequence–specific manner. The presence of V
 
H
 
 mutations in the
clones that had undergone replacement indicated that these B cells were immunocompetent and
could receive and respond to diversification signals. A relationship between these secondary V
 
H
 
gene rearrangements and the autoimmunity characteristic of RA should be considered.
Key words: antibody diversity • recombinase activating genes • immune tolerance • 
autoimmunity • rheumatoid factor
 
Introduction
 
Antibody diversity is initially established in developing B
lymphocytes in the bone marrow by the ordered rearrange-
ment of V, (D), and J elements (1, 2). These rearrange-
ments occur via site-specific recombination events that
classically involve recognition signal sequences (RSS)
 
1
 
comprised of conserved heptamers and less conserved non-
amers (3–5). As this process is largely random, receptors can
be assembled that possess sufficient affinity for autoantigens
to necessitate their elimination. However, such cells may
be afforded another opportunity to express a tolerant re-
ceptor by undergoing secondary V region gene rearrange-
ments that can involve either the H or L chain loci (6–13).
These secondary rearrangements change a major portion of
the antigen-combining site so the new receptor is signifi-
cantly different from the original. The new receptor can
consist of a completely new V
 
L
 
J
 
L
 
 rearrangement or a V
 
H-
 
DJ
 
H
 
 rearrangement that is modified by the replacement of a
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Abbreviations used in this paper:
 
 ds, double-stranded; FR, framework re-
gion; GC, germinal center; LM, ligation-mediated; RA, rheumatoid ar-
thritis; RAG, recombinase activating gene; RF, rheumatoid factor; RSS,
recognition signal sequence(s); RT, reverse transcription. 
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portion of the originally rearranged V segment (“V
 
H
 
 re-
placement” [9]). If these secondary rearrangements provide
the B cell with an acceptable antigenic specificity, it pro-
ceeds to the periphery as a functional B lymphocyte. This
process of secondary rearrangement, presumably initiated
by autoreactivity, has been termed receptor editing (6–8).
In the periphery, mature B cells can develop additional
receptor/antibody diversity during the germinal center
(GC) reaction. Although this process was long considered
to be limited to the accumulation of point mutations (14),
recent studies suggest that more extensive changes in the
primary repertoire can occur by a variety of mechanisms.
These mechanisms include the insertion and/or deletion of
DNA segments of variable lengths (12, 15, 16), and the op-
portunity to again undergo V gene rearrangement. As these
secondary rearrangements are thought to be initiated in
those B cells undergoing the GC reaction that lack ade-
quate affinity for the selecting antigen, this process appears
to be different from receptor editing and therefore has been
termed receptor revision (11, 12, 17, 18).
Furthermore, receptor revision could potentially lead to
autoreactivity if the drive to clonal diversification created
self-reactive receptors that were ineffectively selected
against, because of either genetic or acquired defects in im-
munoregulation. Therefore, this process could play an im-
portant role in the development of certain autoimmune
disorders.
Rheumatoid arthritis (RA) is a relatively common,
chronic, destructive arthropathy that results from an in-
flammatory synovitis of peripheral joints (19). These in-
flammatory processes appear to be mediated by cells of the
myeloid, macrophage, and lymphoid lineages (20). Al-
though there has been considerable controversy regarding
the relative importance of the various cell types and their
products in the inflammatory reactions of RA, it seems
likely that all cell lineages participate in disease pathogene-
sis. B lymphocytes may not be necessary to initiate the in-
flammatory reactions characteristic of RA (21), but B cells
and their products can perpetuate and potentiate these re-
sponses (22–25). This perpetuation most likely involves at
least two functions of B cells: their abilities to present anti-
gen to T cells and to elaborate antibodies. Central to each
of these functions is the (auto)antigenic specificity encoded
in the V regions of the B cell’s Ig molecules. These anti-
genic specificities include the classical anti-IgG/rheumatoid
factor (RF) reactivity (26, 27) as well as other less well-
defined reactivities that presumably are directed at tissue
autoantigens (28–30) and possibly etiologic environmental
antigens (31–33). Furthermore, a recent murine model that
has some features similar to the human disease (34) suggests
that B cells and their products could play an essential role in
the disease process (35, 36).
Histologically, the synovial tissues of some RA patients
contain collections of B and T lymphocytes and follicular
dendritic cells that resemble GCs (37, 38). These pseudo-
GCs possess at least some of the functions of typical GCs,
i.e., they appear to be able to support clonal amplification
and Ig V gene diversification as measured by the accumula-
 
tion of new mutations. In the course of studying the
clonally amplified B lymphocytes that develop V gene
point mutations in the synovial tissues of RA patients, we
identified a series of clones that exhibited V
 
H
 
DJ
 
H
 
 variants
that were apparently generated by V
 
H
 
 replacement. How-
ever, unlike previous studies of V
 
H
 
 replacement in murine
B cell lines (39–42) and transgenic mice (6–8, 43) and in
transformed (44–46) and normal human B lymphocytes
(18, 45), these secondary V
 
H
 
 rearrangements occurred rela-
tively frequently and involved several heptamer-like se-
quences at four distinct locations within V
 
H
 
. Our data sug-
gest that these rearrangements can occur in situ and could
be mediated by products of the recombinase activating
genes (RAGs) in an RSS-specific manner. A preliminary
report of these findings was presented previously (47).
 
Materials and Methods
 
Patient Samples.
 
Synovial tissue was obtained from three pa-
tients who fulfilled the American College of Rheumatology cri-
teria for the diagnosis of RA (48). For patient 1 (a 29-yr-old His-
panic male), synovial tissue was collected from the right and left
hips at the time of bilateral joint replacements; these samples are
labeled ST1R or ST1L, respectively. For patient 2 (a 25-yr-old
Black female) and 3 (a 56-yr-old White female), synovial tissue
was collected from individual knee joints; these samples are la-
beled ST2 and ST3. Each sample was digested with collagenase
type IV, DNase I (both from Worthington Biochemical Corpo-
ration), and hyaluronidase (Sigma-Aldrich) to obtain single cell
suspensions. Mononuclear cells were isolated from these cell sus-
pensions by density gradient centrifugation using Ficoll-Paque
(Amersham Pharmacia Biotech) and then cryopreserved as viable
cells in 20% fetal bovine serum with 10% dimethyl sulfoxide us-
ing a programmable cell freezing machine (CryoMed).
 
Isolation of DNA and RNA and Preparation of cDNA.
 
Geno-
mic DNA was isolated from mononuclear cells using the Pure-
gene DNA isolation kit (Gentra Systems) and total RNA was iso-
lated using Ultraspec RNA (Biotech Laboratories). 1 
 
m
 
g of RNA
was reverse transcribed to cDNA using 200 U Moloney murine
leukemia virus reverse transcriptase (GIBCO BRL/Life Technol-
ogies), 1 U RNase inhibitor (5 Prime 3 Prime), and 20 pmol
oligo dT primer in a total volume of 20 
 
m
 
l. These reagents were
incubated at 42
 
8
 
C for 1 h, heated to 65
 
8
 
C for 10 min to stop the
reactions, and then diluted to a final volume of 100 
 
m
 
l.
 
PCR Amplification of Ig V
 
H
 
 Gene DNA and cDNA.
 
The se-
quences of the primers used in these reactions were published
previously (49). Genomic DNA (100 ng) was amplified using a
sense V
 
H
 
1 family–specific framework region (FR)1 primer in
conjunction with an antisense J
 
H
 
 consensus primer. These reac-
tions were carried out in 50 
 
m
 
l using 5 pmol of each primer and
were cycled with a 9600 GeneAmp System (PerkinElmer) as fol-
lows: denaturation at 94
 
8
 
C for 40 s, annealing at 65
 
8
 
C for 45 s,
and extension at 72
 
8
 
C for 40 s. After 35 cycles, extension was
continued at 72
 
8
 
C for an additional 10 min. cDNA was amplified
using the same sense primer paired with either a C
 
m
 
, C
 
g
 
, or C
 
a
 
antisense primer (50). However, the reactions were cycled as fol-
lows: denaturation at 94
 
8
 
C for 45 s, annealing at 65
 
8
 
C for 45 s,
and extension at 72
 
8
 
C for 45 s. After 35 cycles, extension was
continued at 72
 
8
 
C for an additional 10 min.
 
Creation of DNA and cDNA Libraries and Sequencing of Selected
Clones.
 
V
 
H
 
1-specific DNA and cDNA libraries were created
from the PCR products described above. 10 ng of each PCR 
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product was ligated into pCR2.1 vector and transformed into
INV
 
a
 
F
 
9
 
 competent cells using the TA cloning kit (Invitrogen).
Transformed INV
 
a
 
F
 
9
 
 cell colonies were identified and isolated
by color selection after overnight growth on Luria-Burtani (LB)
agar plates containing X-Gal and ampicillin. Plasmids were iso-
lated from each selected colony using Wizard minipreps
(Promega) after overnight growth in LB broth containing kana-
mycin. The DNA sequences of individual molecular clones were
determined using Big Dye DNA sequencing kit (PerkinElmer)
with M13 forward and reverse primers and an automated genetic
analyzer ABI PRISM 377 (Applied Biosystems). The error rate
calculated for these sequence analyses was 8.36 
 
3 
 
10
 
2
 
4
 
, based on
the detection of 13 mutations in 15,554 nucleotides of C
 
H 
 
genes
of these and other human cDNA V
 
H
 
DJ
 
H
 
-C
 
H
 
 transcripts from RA
synovial B cells. All V
 
H
 
 gene sequences discussed in this study
have been entered in EMBL/GenBank/DDBJ under accession
nos. AF308542–AF308567.
 
PCR Conditions for Ig V
 
H
 
 Gene Fingerprinting Assay.
 
The
original Ig V
 
H
 
 gene fingerprinting assay (51) was modified (52)
into two stages, starting with either genomic DNA or cDNA as
templates. The sequences of the primers used in these reactions
and the details of the two PCR stages have been published previ-
ously (52).
 
Analyses of Ig DNA Breaks by Ligation-mediated PCR.
 
To
avoid adventitious breaks, genomic DNA was prepared by the
agarose plug method (53) from 2–3 
 
3
 
 10
 
5
 
 CD19
 
1
 
 cells isolated
using magnetic beads as described (54). To identify blunt-ended
double-stranded (ds) DNA breaks, ligation-mediated (LM)-PCR
was employed (55). In brief, linker ligation was performed in 25–
50-
 
m
 
l reactions using T4 DNA ligase and the linker-ligated DNA
was diluted with ligation buffer to adjust the amounts of DNA
used in the subsequent seminested PCR (54). 2 
 
m
 
l of linker-
ligated DNA was amplified using a sense V
 
H
 
1 family–specific
leader primer in conjunction with an antisense linker primer
(GCGGTGACCCGGGAGATCTGAATTCAC). These reac-
tions were performed in 25 
 
m
 
l using 5 pmol of each primer and
were cycled as follows: denaturation at 94
 
8
 
C for 30 s, annealing at
63
 
8
 
C for 45 s, and extension at 72
 
8
 
C for 45 s. After 35 cycles, ex-
tension was continued at 72
 
8
 
C for an additional 10 min. Next, 2
 
m
 
l of each PCR product was reamplified with 5 pmol of V
 
H
 
1
family–specific FR1 primer and the same antisense linker primer.
The reactions were carried out in 25 
 
m
 
l and cycled as described
above. After 30 cycles, extension was continued at 72
 
8
 
C for an
additional 10 min. The V
 
H
 
 LM-PCR products were visualized
with ethidium bromide staining.
 
Analyses of RAG-1 Expression by Nested Reverse Transcription
PCR.
 
RAG-1 was amplified from cDNA by nested PCR using
specific primer pairs that flank a 5.2-kb intron in the germline
gene: sense, TGCAGACATCTCAACACTTTGGCCAG; anti-
sense 1, TTTCAAAGGATCTCACCCGGAACAGC; antisense
2, AGCTTAAATTTCCATTCTGAATT. This PCR strategy
has been used successfully to analyze RAG-1 expression in tonsi-
lar GC B cells (56).
 
Results
 
Clonal Amplification among Synovial Tissue B Lymphocytes
 
HCDR3 length is a useful estimator of clonal diversity in
polyclonal B cells (51). Comparisons of HCDR3 lengths
generated from both the genomic DNA and cDNA of the
same sample indicate the relative frequencies and activation
 
states of individual B cell clones in polyclonal populations
(52). Using this combined approach, we analyzed the B
lymphocytes infiltrating the synovial tissues from four dif-
ferent joints of three RA patients. Widespread oligoclonal-
ity was found among the IgM-, IgG-, and IgA-expressing
B cells in the four synovial tissue samples (52; see Figs. 3
and 4, and data not shown). Based on comparisons of the
genomic DNA and cDNA fingerprinting assays, these
clonal expansions involved both activated and memory B
cells. Such clonal expansions are a common and character-
istic feature of the B cell repertoires of RA patients (38, 52,
57–59), and they suggest in situ activation and growth of B
lymphocytes with restricted B cell receptors (BCRs) that
may be reactive with local (auto)antigens.
 
cDNA Sequence Analyses of V
 
H
 
1-expressing B Cell Clones 
Reveal Evidence Consistent with V
 
H
 
 Replacement at Three 
Distinct Sites in FR3
 
To determine if diversification had occurred among the
progeny of these expanded B cell clones, we prepared
V
 
H
 
1-IgM– and V
 
H
 
1-IgG–expressing libraries from cDNA
of the ST1R and ST1L synovial samples and determined
the cDNA sequences of 95 random clones. The V
 
H
 
1 family
was chosen for analysis based on the results of the V
 
H
 
 fin-
gerprinting analyses. As expected, several expanded B cell
clones were found in each sample as indicated by the pres-
ence of identical HCDR3 sequences. In many instances,
these clones contained distinct point mutations in their V
 
H
 
genes, indicating that intraclonal diversification had oc-
curred (data not shown).
Five sets of cDNA clones (Table I) were especially inter-
esting because they contained clonal progeny that exhibited
a significant discordance in the sequence between the 3
 
9
 
and the 5
 
9 regions of their rearranged VHDJH genes (see
Figs. 2–5). Among the members of these clones, there was
an average of .99.9% similarity (usually 100% identity)
from the distal portions of FR3 through HCDR3 to the
end of the CH sequence. In contrast, there was an average
of ,81.6% sequence similarity between the clonal mem-
bers 59 of these portions of FR3. This discordance is con-
sistent with VH replacement (represented schematically in
Fig. 1). However, unlike previous examples of this phe-
nomenon that involved rearrangements to a single site in
FR3 (6–8, 18, 39–46), the rearrangements detected in the
synovial tissue cDNA clones occurred at three distinct sites
spanning FR3 (see Figs. 2–5).
Rearrangements Involving the 39 FR3 Heptamer. Fig. 2
lists an example of VH replacement occurring at the 39 end
of FR3 of two IgG-expressing clones from ST1L (clones
G27 and G29). In this and the following figures, the se-
quence of the original B cell clone is listed above the new
“replaced” B cell clone, with the most similar germline
gene counterparts listed above and below the original and
new rearrangements, respectively. The replacement in Fig.
2 occurs at an embedded heptamer of reverse orientation
(TACTGTG; displayed with black background in the fig-
ure) that has been identified at the end of murine and hu-
man VH genes (39–41, 60). These clones display 100%1154 VH Replacement in Synovial Tissue B Lymphocytes
identity from the embedded heptamer to the end of the
IgG CH sequence determined. In contrast, the 2 clones dif-
fer at 48 positions 59 of the embedded heptamer (80.2%
similarity).
When a homology search was made for the most likely
germline counterpart of the gene segments 59 of the hep-
tamer, G27 was 90.6% similar to the VH 1–8 germline
gene, whereas clone G29 was only 84.3% similar to the
1–8 germline gene. However, the 59 segment of clone G29
was 94.6% similar to the VH 1–69 germline gene. These
comparisons suggest that the two clones diverged by inter-
changing major portions of the VH 1–8 and 1–69 genes up
to the position of the embedded heptamer.
Rearrangements Involving the 59 FR3 Heptamer. The IgG-
expressing clones listed in Fig. 3 demonstrate VH replace-
ment occurring at the 59 end of FR3. These rearrange-
ments utilize a heptamer (CACAGCC) embedded in an
orientation like that found at the 39 end of unrearranged
Table I. Molecular Characterization of the RA Synovial Tissue B Cell Clones That Underwent VH Replacement
Type of diversification
No. of 
mutations
Clone Source
No. of identical
sequences VH gene(s) used Ig isotype VH mutation VH replacement
FR
R/S
CDR
R/S
ST1R M5 cDNA 1 VH 1–58 IgM 22 0/0 0/0
ST1R M1 cDNA 1 VH 1–58 IgM 12 0/1 0/0
ST1R M8 cDNA 1 VH 1–58 IgM 12 0/1 0/0
ST1R M26 cDNA 1 VH 1–58 IgM 12 1/0 0/0
ST1R M6 cDNA 1 VH 1–58/VH 1–18 IgM 11 5/2 1/0
ST1R M31 cDNA 1 VH 1–58/VH 1–24 IgM 11 1/2 0/0
ST1R M10 cDNA 1 VH 1–58/VH 1–69 IgM 11 10/5 4/1
ST1R M17 cDNA 1 VH 1–08 IgM 12 4/4 4/1
ST1R M9 cDNA 1 VH 1–08/VH 1–69 IgM 11 0/1 0/0
ST1R G1 cDNA 1 VH 3–09/VH 1–02 IgG 11 17/3 18/1
ST1R G2 cDNA 1 VH 3–09/VH 1–69 IgG 11 11/6 3/2
ST1L G12 cDNA 1 VH 1–69 IgG 12 8/3 2/1
ST1L G2 cDNA 8 VH 1–69 IgG 12 7/4 2/1
ST1L G32 cDNA 1 VH 1–69 IgG 12 7/4 2/2
ST1L G22 cDNA 1 VH 1–69 IgG 12 9/4 2/1
ST1L G11 cDNA 1 VH 1–69 IgG 12 9/5 5/1
ST1L G19 cDNA 1 VH 1–69/VH 1–08 IgG 11 10/6 4/1
ST1L G8 cDNA 1 VH 1–08 IgG 12 10/5 4/1
ST1L G27 cDNA 1 VH 1–08 IgG 12 13/4 4/1
ST1L G29 cDNA 1 VH 1–08/VH 1–69 IgG 11 7/2 3/1
ST2 14 DNA 5 VH 1–46 Indeterminate 22 0/0 0/0
ST2 10 DNA 1 VH 1–46/VH 1–02 Indeterminate 11 5/3 6/2
ST2 6 DNA 2 VH 1–58 Indeterminate 12 0/0 1/0
ST2 31 DNA 1 VH 1–18/VH 1–46 Indeterminate 11 3/1 0/0
ST2 2 DNA 2 VH 1–46 Indeterminate 22 0/0 0/0
ST2 26 DNA 1 VH 1–46/VH 1–69 Indeterminate 11 6/2 0/0
The nucleotide sequences of 95 cDNA clones and 36 genomic DNA clones were determined.  Only those clones that contained progeny exhibiting
VH replacement are listed. R, replacement; S, silent.1155 Itoh et al.
VH genes. This heptamer lies 52 nucleotides upstream of
the 39 heptamer mentioned above.
As in the previous examples, there is 100% identity be-
tween the 2 clones from the embedded heptamer to the
end of the CH sequence, but only 82.6% similarity between
these 2 clones upstream of the heptamer (33 differences).
The upstream portion of clone G11 was most similar to the
VH 1–69 germline gene (93.7%), whereas the same portion
of clone G19 was most similar to the VH 1–08 germline
gene (92.6%).
Rearrangements Involving a Heptamer Embedded between the
59 and 39 FR3 Sites. The clones listed in Fig. 4 illustrate
VH replacement occurring at a heptamer (CACGGCC) lo-
cated between the two sites mentioned above. This “mid-
position FR3 heptamer” is oriented like the 59 FR3 hep-
tamer. The examples listed in the figure (M17 and M9) are
members of an IgM-expressing clone from a different ana-
tomic site of patient no. 1. In this case, there is only a one-
nucleotide difference between the two clones from the
heptamer to the end of the IgM CH sequence; this differ-
ence occurs outside of the HCDR3 in FR4. However,
there are 43 nucleotide differences upstream of the hep-
tamer (81.2% similarity). The 59 portion of M9 derives
from the VH 1–69 germline gene (99.6% similar), whereas
the same portion of clone M17 is from the VH 1–8 germline
gene (94.2% similar to 1–8 and only 81.9% similar to 1–69).
Figure 2. cDNA clones exhibiting VH replace-
ment at the 39 FR3 embedded heptamer.  Two
VH1-IgG1 clones from ST1L (G27 and G29) are
aligned centrally with their most similar germline
gene counterparts listed above and below. The gaps
in the sequences represent the boundaries between
the various FR and CDR. The 39 FR3 embedded
heptamers are displayed with black backgrounds
and the HCDR3 are boxed. Nucleotide differences
between the two clones are indicated by dots and
identities are indicated by asterisks. Nucleotide dif-
ferences between the individual clones and their
germline counterparts are indicated by letters and
the identities are indicated by dashes. Note that the
HCDR3 of the two clones are identical, whereas
the VH segments upstream of the heptamer are very
different between the two clones and resemble dif-
ferent germline genes. Based on either genealogical
trees or point mutations, the VHDJH rearrangement
of the original B cell clone is listed above the new
VHDJH rearrangement.
Figure 1. Schematic representation of VH re-
placement occurring at the four heptameric
sites defined in this study. The top panel illus-
trates a typical VH to DJH rearrangement. The
lower panels illustrate the four types of VH re-
placement documented in this study. VH seg-
ment replacement occurred at four discrete
heptamer-like sequences, three located in FR3
(39 FR3 heptamer, mid-position FR3 hep-
tamer, and 59 FR3 heptamer) and one located
in CDR2 (CDR2 heptamer).1156 VH Replacement in Synovial Tissue B Lymphocytes
Multiple Distinct Rearrangements Using Different Heptamers
within the Same Original B Cell Clones. We detected two
examples of multiple independent VH gene replacement
events occurring in distinct progeny of single progenitor B
cell clones. Fig. 5 A illustrates three replacements in the
progeny of the ST1R M26 clone, each occurring at a dif-
ferent heptameric site. Thus, the rearranged M26 VHDJH
was replaced at the 39 FR3 heptamer by a new VH 1–69
germline gene to become clone M10. In addition, a re-
placement occurred in a different subclone involving a new
VH 1–18 germline gene at the mid-position FR3 heptamer,
yielding clone M6. Finally, a replacement using the VH 1–24
germline gene occurred at the 59 FR3 heptamer, giving rise
to clone M31.
The examples in Fig. 5 B represent two distinct VH1
gene replacement events (VH 1–2 and 1–69 segments) that
occurred in a clone that originally used a VH3 gene (VH
3–09). Both of these rearrangements used the same mid-
position FR3 heptamer. The identity of the original clone
as a member of the VH3 family is clear because the nucle-
otides downstream from the embedded heptamer are identi-
cal to VH 3–09 and are not found in any VH1 family genes.
DNA Sequence Analyses of VH1-expressing B Cell Clones from 
a Different Patient Confirm and Extend VH Replacement Events
Based on these findings, we searched for evidence of VH
replacement at the genomic DNA level to avoid the possi-
bility that the cDNA results represented artifacts of reverse
transcription (RT)-PCR. In addition, these studies were
carried out using synovial tissue (ST2) from a different RA
patient to assure that this phenomenon was not unique to a
single patient.
Fig. 6 shows the three examples of VH replacement
found in the VH1-expressing DNA library from sample
ST2. Fig. 6, A and B, confirm the occurrence of VH re-
placement occurring at the 59 FR3 heptamer and the mid-
position FR3 heptamer.
However, Fig. 6 C documents a VH replacement event
that we had not detected at the cDNA level. This replace-
ment occurred at a heptamer (CACAGAA) embedded in
HCDR2. As in the previous examples, the 2 clones are
identical 39 of the embedded heptamer, but only 82.3%
similar 59 of the heptamer (25 differences). Both clones are
identical to their respective germline genes (VH 1–46 and
1–69) 59 of the heptamer.
Figure 3. cDNA clones exhibiting VH replace-
ment at the 59 FR3 embedded heptamer.  Two
VH1-IgG1 clones from ST1L (G11 and G19) are
aligned as in Fig. 1. The original VHDJH rearrange-
ment is listed above the new VHDJH rearrangement.
Figure 4. cDNA clones exhibiting VH replace-
ment at a heptamer embedded between the 59 and
39 FR3 heptamers (mid-position FR3 heptamer).
See the legend to Fig. 1.1157 Itoh et al.
Ig VH Gene Diversification among the Clones Undergoing
VH Replacement
As indicated in Table I, the VH replacement events de-
tected in these synovial tissue samples usually occurred in
B cells that had already had significant antigenic exposure
and had accumulated V gene mutations. In addition, a
comparison of the average numbers of mutations in the
original clonal members (236 mutations/22 sequences;
10.73%) and the numbers of mutations in the “replaced”
clones (144 mutations/11 sequences; 13.09%) indicates
that the diversification process continued in those clones
that had undergone VH replacement. Therefore, these B
cells remained immunocompetent after the secondary rear-
rangement event and received and responded to diversifi-
cation signals.
Three genealogical trees that display examples of these
clonal diversification events are presented in Fig. 7, along
with the numbers, types, and locations of the VH gene mu-
tations that occurred in the various clonal members.
Use of LM-PCR to Detect DNA Breaks at the Sites of
VH Replacement
We used VH family–specific LM-PCR to probe for
blunt-ended dsDNA breaks at the embedded heptamers in
the ST2 and ST3 synovial samples. Such products could
represent intermediates of VH replacement. Human bone
marrow cells were used as positive controls and fibroblasts
as negative controls in these studies. VH-containing prod-
ucts were obtained from both the synovial tissue and bone
marrow B cell samples, whereas no products were obtained
from the fibroblast DNA. For the synovial tissue samples,
two products of z300 and z250 bp were detected (Fig. 8).
The DNA sequences of VH1-expressing clones (n 5 50)
from the PCR products of ST3 revealed the linker ligated
Figure 5. cDNA clones exhibiting multiple dis-
tinct secondary rearrangements using different hep-
tamers. (A) Three distinct replacement events that
occurred in the progeny of the parental ST1R M26
clone are listed below the original clone. Note that
each clone used a different embedded heptamer to
accomplish the replacement event. The most simi-
lar germline genes for M10 (1–69), M6 (1–18), and
M31 (1–24) are not listed. (B) Two distinct re-
placement events that occurred in the progeny
(ST1R G1 and G2) of a VH3–09–expressing B cell
clone. It is clear that the original clone expressed a
VH3 gene because the nucleotides downstream
from the embedded heptamer are identical to VH
3-09 and are not found in any VH1 family genes.1158 VH Replacement in Synovial Tissue B Lymphocytes
at or within the 59 FR3 heptamer (300-bp product) and
the 39 FR3 heptamer (250-bp product), indicating that
blunt dsDNA ends were available at these sites (data not
shown).
RAG-1 Gene Expression in the Synovial Tissues of RA Patients
As V(D)J recombination requires RAG proteins, the iden-
tification of RAG gene expression would provide a possible
mechanism for the identified DNA breaks and the secondary
VH gene segment rearrangements. Therefore, we used RT-
PCR to search for RAG-1 gene expression in synovial tissue
samples.
As shown in Fig. 9, RAG-1 mRNA was readily detected
in several synovial tissue samples (lanes 2–5) and from hu-
Figure 6. DNA clones exhibiting VH replacements at the 59 FR3 hep-
tamer and the mid-position FR3 heptamer and at a heptamer embedded
in HCDR2. (A) An example of a replacement that occurred at the 59
FR3 heptamer. Note that there is another potential heptameric site lo-
cated 12 bp upstream of the 59 FR3 heptamer (highlighted in light gray).
(B) An example of a replacement that occurred at the mid-position FR3
heptamer. (C) An example of a replacement that occurred at a heptamer
located in HCDR2.
man bone marrow (lane 1). The lack of RAG-1 gene ex-
pression in human fibroblasts (lane 6) and direct sequence
analyses of these products (data not shown) confirmed the
specificity of these reactions. As the primers used for these
reactions flank a 5.2-kb intron in the RAG-1 gene, these
180-bp products could not have been generated from ge-
nomic DNA templates. Furthermore, preliminary single-
cell PCR and cDNA sequencing analyses suggest expres-
sion of RAG-1 in a subset (z20–30%) of CD191 B cells
from ST2 and ST3 (data not shown).
Discussion
In this study we identified four types of secondary VH
gene rearrangements that occurred among clonally related
B cells that were expanded in the synovial tissues of differ-
ent RA patients. Although chimeric V gene sequences can
be generated artifactually by crossover events during PCR
and cloning, we believe that it is highly unlikely that our
findings represent artifacts because these rearrangements (a)
were observed in three different synovial tissue samples
from two RA patients, (b) were documented at both the
cDNA and genomic DNA levels, (c) occurred only at sites
in the VH genes that exhibited heptamer-like sequences,
and (d) were always in-frame and coded translatable pro-
teins. (e) Finally, and perhaps most convincingly, is the
finding that transcripts from progeny of two different
clones displayed replacements of different genes either at
the same heptamer (Fig. 5 A) or at distinct heptamers (Fig.
5 B). The possibility that replicates of the same DNA seg-
ments would have developed crossover artifacts involving
different genes either at the same position or at different
positions, each flanked by a cryptic RSS, is remote.
Because these VH replacement events occurred in B cells
that exhibited dsDNA breaks at heptamer-like sequences
(Fig. 8) and expressed RAG-1 proteins (Fig. 9), we believe
that these V gene replacements were RSS specific and
RAG mediated. Such a process has been shown to occur in
vitro (39–42, 61) and in vivo (6–9, 18, 43–46), and the
identification of circular DNA containing the outgoing VH
gene joined to the RSS of the incoming VH gene (42, 61)
suggests that the process involves the RAG proteins and
the V(D)J recombination process. However, these rear-
rangements require the formation of hybrid joints between
the coding end of the incoming VH gene and the signal end
of the outgoing VH gene segment (5, 9, 18).
Nevertheless, we cannot exclude the possibility that
these VH replacement events were mediated by a non–site-
specific, general recombination process such as gene con-
version, a mechanism that is involved in the diversification
of the l5/14.1 component of the pre-BCR in humans (62)
as well as the BCR of chickens (63, 64) and rabbits (65,
66). If gene conversion is responsible for these secondary
recombination events, the site of cross-strand exchange
could be located anywhere downstream of the first mis-
match and upstream of the next mismatch between the in-
coming/donor germline VH gene sequence and the outgo-
ing/recipient rearranged gene segment.1159 Itoh et al.
The data that favor a RAG-mediated recombination
event include: (a) the size of the fragments being replaced,
as gene conversion usually involves smaller segments of
DNA; (b) the apparent insertion of the new DNA fragment
at specific sites (heptamer-like sequences), as the insertion
of DNA via gene conversion is generally viewed as a non–
site-specific process; (c) the presence of dsDNA breaks at
these heptamer-like sequences, especially those clones with
multiple distinct rearrangements (Fig. 5); and (d) the ex-
pression of RAG-1 in these B cell populations. The data
that are atypical for classical V(D)J recombination include
the absence of detectable nonameric sequences 12 or 23 bp
from the cryptic heptamers (vide infra) and the lack of cod-
ing end processing at the junctions of the new rearrange-
ments (Figs. 2–5). However, these latter findings are not
completely incompatible with a RAG-mediated process, as
nonamers are not essential for in vitro rearrangements (67)
and in situations in which hybrid joint formation is facili-
tated (e.g., Ku knockout mice [68]), the hybrid junctions
frequently do not display evidence of N-insertions and ex-
onuclease activity (69). Thus, both site-specific and general
recombination mechanisms may be responsible for these
VH replacement events, and the two mechanisms may not
be mutually exclusive. Indeed, a mechanism involving
RAG-mediated cleavage at cryptic RSS followed by DNA
segment exchange mediated by homologous recombina-
tion may not be unreasonable. Clearly, further study will
be required to determine the relative contributions of these
two mechanisms. Nevertheless, at this point our data sug-
gest a likely role for cryptic heptamers and RAG in these
secondary VH gene rearrangements.
In this study we identified four cryptic heptamers that
appeared to be involved in these secondary rearrangements.
Three of these heptamers were within FR3 (Figs. 2–5, and
Fig. 6, A and B) and one in HCDR2 (Fig. 6 C). The hep-
Figure 7. Representative examples of VH diversification occurring in the B cell clones that exhibit VH replacements. In each instance (A, B, and C),
the identified cDNA clones are represented by filled circles and the presumed (unidentified) clones are represented by hashed circles. The numbers of
mutations are contained within the circles and their locations (FR vs. CDR) and types (replacement [R] vs. silent [S]) are displayed adjacent to the circles.
Figure 8. LM-PCR identifies dsDNA fragments generated by cleavage
at the 59 and 39 heptamers. Genomic DNA was prepared from CD191
cells from two synovial tissue samples (lanes 1 and 2) and from human
bone marrow (lane 3) by the agarose plug method (reference 53). LM-
PCR was then used to identify blunt-ended dsDNA breaks (reference 55).
The VH-containing products of these reactions were visualized with ethid-
ium bromide staining. The 320- and 249-bp bands contained DNA frag-
ments with the linker attached at or in the 59 (320 bp) and 39 (249 bp) hep-
tamers. Lane 4 is a template-deprived negative control. M, marker lane.1160 VH Replacement in Synovial Tissue B Lymphocytes
tamer located at the end of FR3 was in an inverse orienta-
tion like that found at the 59 end of D segments and corre-
sponded exactly to that described previously in murine VH
gene replacement events (9, 39–41). The 59 FR3 hep-
tamer, the mid-position FR3 heptamer, and the heptamer
in HCDR2 were oriented like those found at the 39 ends
of unrearranged VH genes. All of these heptamers displayed
the essential 59 three nucleotides CAC (67), followed by
variations on the expected AGTG sequence (e.g., AGCC,
GGCC). In vitro studies (67) indicate that these sequences
will permit recombination, albeit at reduced efficiencies. It
is possible that any heptamer that has a CAC motif at its 59
end can act as an embedded RSS for secondary rearrange-
ments. In this regard, the genomic DNA clones listed in
Fig. 6 A (ST2 6 and ST2 31) exhibit a heptameric sequence
(CACATCC; highlighted in light gray in Fig. 6 A) 12 nu-
cleotides upstream of the 59 FR3 heptamer that could have
functioned as an RSS in this instance. If this is the case,
then this represents still another FR3 heptamer in addition
to the three previously discussed.
Classical V(D)J recombination requires a heptamer, a
spacer of either 12 or 23 bp, and a nonamer (ACAAAA-
ACC-39 [3, 4]). We could not define a standard nonamer
sequence 12 or 23 bp from the heptamers described, al-
though the clones listed in Fig. 5 B display a potential non-
amer 12 bp downstream of the cryptic heptamer; this se-
quence spans the FR3–CDR3 junction. Nevertheless, the
requirements for effective nonamers are far less stringent
than for heptamers (67), and in vitro recombination studies
suggest that nonamers may not be necessary (5). The in-
ability to define a classical nonamer is consistent with pre-
vious studies of VH replacement (9) and led to the sugges-
tion that there might be a different nonamer sequence
specific for V gene replacement (9).
Secondary VH gene recombination events would be ex-
pected to involve incoming genes that are located upstream
of the originally rearranged (and outgoing) VH gene. In one
combination it was impossible to determine which was the
original gene (ST1R M17 and M9). However, in 10 in-
stances this determination was clear, either because of criti-
cal nucleotide point differences (e.g., ST2 2®ST2 26; see
the 9 nucleotides within the common downstream FR3 se-
quence in Fig. 5 C) or because of an obvious genealogical
progression (e.g., ST1L G11®G19; ST1L G27®G29;
ST1R M26®M10, M6, and M31; ST1R G1 and G2 [see
Fig. 6]). In 5 of the 10 instances in which chronology was
clear, the incoming gene was located 59 of the original out-
going gene. However, in five events this was not the case.
Therefore, in these instances the new rearrangement may
have involved a VH gene residing on the other chromo-
some or the original locus may have been inverted (e.g., by
a D-JH rearrangement that involved the heptamer at the 39
end of a D segment [17]).
The VH 1–69 gene was frequently involved in these VH
replacement events (6/11 instances), despite the fact that it
is not overexpressed in the normal human B cell repertoire
(70). This suggests that certain VH genes may be favored in
the replacement process. This is consistent with the find-
ings that discrete VH genes were nonstochastically involved
in spontaneous (71) and induced (61) VH replacement
events in murine B cell lines.
We were surprised that these secondary VH rearrange-
ments occurred so frequently in these synovial tissue B
cells. 8/95 VH1-expressing cDNA clones and 3/36 VH1-
expressing genomic DNA clones from 3 anatomically dis-
tinct synovial tissues exhibited this phenomenon (Table I).
This represents a frequency of 8.4%. As our DNA sequenc-
ing strategies restricted us to identifying VH replacements
that involved VH1 family genes replacing VH1 genes, the
frequency of these events might have been higher had we
searched for VH replacements that involved VH segments
from other families being incorporated into VH1.
It remains to be determined whether this high frequency
of VH replacement events represents a feature of normal
GC reactions or of the ectopic GC reactions identified in
RA (37, 38). In this regard, Wilson et al. (18) documented
VH replacement occurring at a 59 FR3 heptamer found in
VH4 family genes in a subset of tonsilar B cells that express
solely IgD and exhibit an especially high frequency of so-
matic point mutations (72). As our studies were performed
with unfractionated B cells, we cannot determine the pre-
cise cellular subset in which these events occurred. How-
ever, as all of the cDNA transcripts analyzed in our study
were of the IgM and IgG varieties (Figs. 2–5), VH replace-
ment is not limited to IgD1IgM2 B cells. In addition, the
appearance of point mutations in every case of VH replace-
ment (Table I) suggests that these B cells maintained a
functional BCR that promoted viability (73) and permitted
continued clonal expansion and somatic hypermutation in
the “replaced” clone. Meffre et al. recently described a sub-
set of human B lymphocytes marked by the coexpression
of conventional and surrogate L chains that is enriched in
the synovial tissues of certain RA patients (74). These cells
express RAG mRNA and show evidence of receptor edit-
ing. It will be interesting to see if this unusual B cell subset
is a component of the B cell expansions that are character-
istic of RA and that can undergo VH replacement.
These surprisingly frequent VH replacement events may
have significance for the autoreactivity seen in RA, as they
Figure 9. RAG-1 gene expression in the synovial tissues of RA pa-
tients. RAG-1 was readily detected by RT-PCR in the cDNA obtained
from several synovial tissue samples (lanes 2–5) and from human bone
marrow (lane 1). Lane 6 is a negative control (human fibroblast cDNA)
and lane 7 is a template-deprived negative control. PCR products and
DNA markers were visualized by ethidium bromide staining after agarose
gel electrophoresis. M, marker lane.1161 Itoh et al.
could either maintain or break self-tolerance. RA is charac-
terized classically by the expansion of RF-producing B cells
that often increase in affinity as the disease progresses (75)
and that correlate with disease severity (76). Furthermore,
B cells and plasma cells with this autospecificity are en-
riched to very high numbers within the synovial tissues of
RA patients (77). As it is clear from transgenic mouse mod-
els of autoimmunity that secondary rearrangements of ei-
ther VH or VL can lead to non–self-reactive receptors (6–9,
43), it seems reasonable that VH replacement of autoreac-
tive BCR may be occurring in RA. However, we should
stress that we do not know the antigenic reactivities of the
B cell clones involved in the VH replacement events re-
ported in this study.
However, it also seems reasonable that because receptor
revision may be diversity (not tolerance) driven (56, 78), it
could lead to autoimmunity. Indeed, several recent studies
support this notion (11, 79). Most relevant is the study of
Brard et al. documenting that anergic B cells from autoim-
mune prone mice could be activated to produce patho-
genic autoantibodies after somatic mutation and receptor
revision (11). The fact that the VH 1–69 gene, which ap-
pears to be a preferred donor in the VH replacement events
detected in synovial tissue B cells, is frequently used to as-
semble RF (80) may support the notion that revision can
inadvertently lead to autoreactivity.
The ectopic GC reactions that take place in the synovial
tissues of RA patients may compound this tendency. As
these GC reactions occur within a microenvironment that
does not normally support B cell diversification, they may
not provide the same types and/or relative quantities of di-
versification signals as natural GCs. This could lead to dif-
ferences in the degrees that various diversification mecha-
nisms are employed (e.g., somatic mutation versus receptor
revision) or in their regulation (e.g., lack of occurrence or
selection of replacement mutations at appropriate rates and
locations that could lead to dysfunctional BCRs and/or to
the initiation of autoreactivity). In the latter regard, the VH
gene sequences derived from the synovial tissue B cells of
our RA cases in many instances failed to exhibit the types
of replacement to silent mutation ratios typically seen in
antigen-selected immune reactions (Fig. 7 [81, 82]). Fur-
thermore, they did not localize to RGYW motifs (83) with
the expected frequencies (data not shown), a feature also
seen in B lymphocytes from some patients with another
autoimmune disorder, systemic lupus erythematosus (84).
Thus, the nonphysiologic nature of the rheumatoid syn-
ovial GC–like environment or a primary defect in the mu-
tation apparatus may support dysregulated B cell diversifi-
cation events. These dysregulated events, combined with a
defect in selection against autoreactivity, either genetic or
acquired, and the provision of T cell help, might play an
important role in the immunopathogenesis of autoimmune
disorders such as RA.
The authors thank Drs. Martin Weigert and Michel Nussenzweig
for their valuable discussions and Drs. Jack Silver, Charles C. Chu,
and Peter K. Gregersen for their critical review of the manuscript. 
This work was supported in part by U.S. Public Health Service
grant AI10811 from the National Institute of Allergy and Infectious
Diseases, National Institutes of Health, by the Leonard Wagner Au-
toimmunity Research Fund, The Jerry and Cecile Shore Fund for
Immunologic Research, and by the Richard and Nancy Leeds
Fund of the Department of Medicine of North Shore University
Hospital.
Submitted: 2 May 2000
Revised: 4 August 2000
Accepted: 24 August 2000
References
1. Tonegawa, S. 1983. Somatic generation of antibody diversity.
Nature. 302:575–581.
2. Alt, F.W., E.M. Oltz, F. Young, J. Gorman, G. Taccioli, and
J. Chen. 1992. VDJ recombination. Immunol. Today. 13:306–
314.
3. Early, P., H. Huang, M. Davis, K. Calame, and L. Hood.
1980. An immunoglobulin heavy chain variable region gene
is generated from three segments of DNA: VH, D and JH.
Cell. 19:981–992.
4. Sakano, H., R. Maki, Y. Kurosawa, W. Roeder, and S.
Tonegawa. 1980. Two types of somatic recombination are
necessary for the generation of complete immunoglobulin
heavy-chain genes. Nature. 286:676–683.
5. Gellert, M. 1997. Recent advances in understanding V(D)J
recombination. Adv. Immunol. 64:39–64.
6. Gay, D., T. Saunders, S. Camper, and M. Weigert. 1993.
Receptor editing: an approach by autoreactive B cells to es-
cape tolerance. J. Exp. Med. 177:999–1008.
7. Radic, M.Z., J. Erikson, S. Litwin, and M. Weigert. 1993. B
lymphocytes may escape tolerance by revising their antigen
receptors. J. Exp. Med. 177:1165–1173.
8. Tiegs, S.L., D.M. Russell, and D. Nemazee. 1993. Receptor
editing in self-reactive bone marrow B cells. J. Exp. Med.
177:1009–1020.
9. Chen, C., Z. Nagy, E.L. Prak, and M. Weigert. 1995. Im-
munoglobulin heavy chain gene replacement: a mechanism
of receptor editing. Immunity. 3:747–755.
10. Bertrand, F.E., R. Golub, and G.E. Wu. 1998. V(H) gene re-
placement occurs in the spleen and bone marrow of non-
autoimmune quasi-monoclonal mice. Eur. J. Immunol. 28:
3362–3370.
11. Brard, F., M. Shannon, E.L. Prak, S. Litwin, and M.
Weigert. 1999. Somatic mutation and light chain rearrange-
ment generate autoimmunity in anti–single-stranded DNA
transgenic MRL/lpr mice. J. Exp. Med. 190:691–704.
12. de Wildt, R.M., R.M.A. Hoet, W.J. van Venrooij, I.M.
Tomlinson, and G. Winter. 1999. Analysis of heavy and light
chain pairings indicates that receptor editing shapes the hu-
man antibody repertoire. J. Mol. Biol. 285:895–901.
13. Lopez-Macias, C., U. Kalinke, M. Cascalho, M. Wabl, H.
Hengartner, R.M. Zinkernagel, and A. Lamarre. 1999. Sec-
ondary rearrangements and hypermutation generate sufficient
B cell diversity to mount protective antiviral immunoglobu-
lin responses. J. Exp. Med. 189:1791–1798.
14. Kelsoe, G. 1996. Life and death in germinal centers (redux).
Immunity. 4:107–111.
15. Wilson, P., Y.J. Liu, J. Banchereau, J.D. Capra, and V. Pas-
cual. 1998. Amino acid insertions and deletions contribute to
diversify the human Ig repertoire. Immunol. Rev. 162:143–
151.1162 VH Replacement in Synovial Tissue B Lymphocytes
16. Goossens, T., U. Klein, and R. Kuppers. 1998. Frequent oc-
currence of deletions and duplications during somatic hyper-
mutation: implications for oncogene translocations and heavy
chain disease. Proc. Natl. Acad. Sci. USA. 95:2463–2468.
17. Nemazee, D., and M. Weigert. 2000. Revising B cell recep-
tors. J. Exp. Med. 191:1813–1817.
18. Wilson, P.C., K. Wilson, Y.-J. Liu, J. Banchereau, V. Pas-
cual, and J.D. Capra. 2000. Receptor revision of immuno-
globulin heavy chain variable region genes in normal human
B lymphocytes. J. Exp. Med. 191:1881–1894.
19. Harris, E.D., Jr. 1990. Rheumatoid arthritis. Pathophysiology
and implications for therapy. N. Engl. J. Med. 322:1277–
1289.
20. Feldmann, M., F.M. Brennan, and R.N. Maini. 1996. Rheu-
matoid arthritis. Cell. 85:307–310.
21. Good, R., and W. Mazzitello. 1957. The simultaneous oc-
currence of rheumatoid arthritis and agammaglobulinemia. J.
Lab. Clin. Med. 49:343–357.
22. Rawson, A.J., J.L. Hollander, F.P. Quismorio, and and N.M.
Abelson. 1969. Experimental arthritis in man and rabbit de-
pendent upon serum anti-immunoglobulin factors. Ann. NY
Acad. Sci. 168:188–194.
23. Holmdahl, R., C. Vingsbo, J.A. Mo, E. Michaelsson, V.
Malmstrom, L. Jansson, and U. Brunsberg. 1995. Chronicity
of tissue-specific experimental autoimmune disease: a role for
B cells? Immunol. Rev. 144:109–135.
24. Zhao, Y.X., A. Abdelnour, R. Holmdahl, and A. Tarkowski.
1995. Mice with the xid B cell defect are less susceptible to
developing Staphylococcus aureus-induced arthritis. J. Immunol.
155:2067–2076.
25. Taylor, P.C., C. Plater-Zyberk, and R.N. Maini. 1995. The
role of the B cells in the adoptive transfer of collagen-induced
arthritis from DBA/1 (H-2q) to SCID (H-2d) mice. Eur. J.
Immunol. 25:763–769.
26. Waaler, E. 1940. On the occurrence of a factor in human se-
rum activating the specific agglutination of sheep blood cor-
puscles. Acta Pathol. Microbiol. Scand. 17:172–188.
27. Rose, H.M., C. Ragan, E. Pearce, and M.O. Lipman. 1948.
Differential agglutination of normal and sensitized sheep
erythrocytes by sera of patients with rheumatoid arthritis.
Proc. Soc. Exp. Biol. Med. 68:1–6.
28. Clague, R.B., K. Morgan, I. Reynolds, and H.J. Williams.
1994. The prevalence of serum IgG antibodies to type II col-
lagen in American patients with rheumatoid arthritis. Br. J.
Rheumatol. 33:336–338.
29. Snowden, N., I. Reynolds, K. Morgan, and L. Holt. 1997. T
cell responses to human type II collagen in patients with
rheumatoid arthritis and healthy controls. Arthritis Rheum. 40:
1210–1218.
30. Schellekens, G.A., B.A. de Jong, F.H. van den Hoogen, L.B.
van de Putte, and W.J. van Venrooij. 1998. Citrulline is an
essential constituent of antigenic determinants recognized by
rheumatoid arthritis-specific autoantibodies. J. Clin. Invest.
101:273–281.
31. Phillips, P.E. 1988. Evidence implicating infectious agents in
rheumatoid arthritis and juvenile rheumatoid arthritis. Clin.
Exp. Rheumatol. 6:87–94.
32. Kouri, T., J. Petersen, G. Rhodes, K. Aho, T. Palosuo, M.
Heliovaara, H. Isomaki, R. von Essen, and J.H. Vaughan.
1990. Antibodies to synthetic peptides from Epstein-Barr nu-
clear antigen-1 in sera of patients with early rheumatoid ar-
thritis and in preillness sera. J. Rheumatol. 17:1442–1449.
33. Hajeer, A.H., A.J. MacGregor, A.S. Rigby, W.E. Ollier, D.
Carthy, and A.J. Silman. 1994. Influence of previous expo-
sure to human parvovirus B19 infection in explaining suscep-
tibility to rheumatoid arthritis: an analysis of disease discor-
dant twin pairs. Ann. Rheum. Dis. 53:137–139.
34. Kouskoff, V., A.S. Korganow, V. Duchatelle, C. Degott, C.
Benoist, and D. Mathis. 1996. Organ-specific disease pro-
voked by systemic autoimmunity. Cell. 87:811–822.
35. Korganow, A.S., H. Ji, S. Mangialaio, V. Duchatelle, R. Pe-
landa, T. Martin, C. Degott, H. Kikutani, K. Rajewsky, J.L.
Pasquali, C. Benoist, and D. Mathis. 1999. From systemic T
cell self-reactivity to organ-specific autoimmune disease via
immunoglobulins. Immunity. 10:451–461.
36. Matsumoto, I., A. Staub, C. Benoist, and D. Mathis. 1999.
Arthritis provoked by linked T and B cell recognition of a
glycolytic enzyme. Science. 286:1732–1735.
37. Randen, I., O.J. Mellbye, O. Forre, and J.B. Natvig. 1995.
The identification of germinal centres and follicular dendritic
cell networks in rheumatoid synovial tissue. Scand. J. Immu-
nol. 41:481–486.
38. Schroder, A.E., A. Greiner, C. Seyfert, and C. Berek. 1996.
Differentiation of B cells in the nonlymphoid tissue of the
synovial membrane of patients with rheumatoid arthritis.
Proc. Natl. Acad. Sci. USA. 93:221–225.
39. Kleinfield, R., R.R. Hardy, D. Tarlinton, J. Dangl, L.A.
Herzenberg, and M. Weigert. 1986. Recombination be-
tween an expressed immunoglobulin heavy-chain gene and a
germline variable gene segment in a Ly 11 B-cell lymphoma.
Nature. 322:843–846.
40. Reth, M., P. Gehrmann, E. Petrac, and P. Wiese. 1986. A
novel VH to VHDJH joining mechanism in heavy-chain-
negative (null) pre-B cells results in heavy-chain production.
Nature. 322:840–842.
41. Kleinfield, R.W., and M.G. Weigert. 1989. Analysis of VH
gene replacement events in a B cell lymphoma. J. Immunol.
142:4475–4482.
42. Covey, L.R., P. Ferrier, and F.W. Alt. 1990. VH to VHDJH
rearrangement is mediated by the internal VH heptamer. Int.
Immunol. 2:579–583.
43. Cascalho, M., J. Wong, and M. Wabl. 1997. VH gene re-
placement in hyperselected B cells of the quasimonoclonal
mouse. J. Immunol. 159:5795–5801.
44. Deane, M., and J.D. Norton. 1990. Immunoglobulin heavy
chain gene rearrangement involving V-V region recombina-
tion. Nucleic Acids Res. 18:1652.
45. Brokaw, J.L., S.M. Wetzel, and B.A. Pollok. 1992. Con-
served patterns of somatic mutation and secondary VH gene
rearrangement create aberrant Ig-encoding genes in Epstein-
Barr virus-transformed and normal human B lymphocytes.
Int. Immunol. 4:197–206.
46. Choi, Y., S.J. Greenberg, T.L. Du, P.M. Ward, P.M. Over-
turf, M.L. Brecher, and M. Ballow. 1996. Clonal evolution
in B-lineage acute lymphoblastic leukemia by contemporane-
ous VH-VH gene replacements and VH-DJH gene rear-
rangements.  Blood. 87:2506–2512.
47. Itoh, K., R. Furie, E. Chartash, R. Jain, and N. Chiorazzi.
1999. Rheumatoid arthritis synovial B cells exhibit novel and
unexpected features of the immunoglobulin V gene mutation
process. Arthritis Rheum. 42:S85.
48. Arnett, F.C., S.M. Edworthy, D.A. Bloch, D.J. McShane,
J.F. Fries, N.S. Cooper, L.A. Healey, S.R. Kaplan, M.H. Li-
ang, H.S. Luthra, et al. 1988. The American Rheumatism
Association 1987 revised criteria for the classification of rheu-
matoid arthritis. Arthritis Rheum. 31:315–324.1163 Itoh et al.
49. Fais, F., F. Ghiotto, S. Hashimoto, B. Sellars, A. Valetto, S.L.
Allen, P. Schulman, V.P. Vinciguerra, K. Rai, L.Z. Rassenti,
et al. 1998. Chronic lymphocytic leukemia B cells express re-
stricted sets of mutated and unmutated antigen receptors. J.
Clin. Invest. 102:1515–1525.
50. Fais, F., B. Sellars, F. Ghiotto, X.J. Yan, M. Dono, S.L.
Allen, D. Budman, K. Dittmar, J. Kolitz, S.M. Lichtman, et
al. 1996. Examples of in vivo isotype class switching in IgM1
chronic lymphocytic leukemia B cells. J. Clin. Invest. 98:
1659–1666.
51. Deane, M., and J.D. Norton. 1991. Immunoglobulin gene
‘fingerprinting’: an approach to analysis of B lymphoid
clonality in lymphoproliferative disorders. Br. J. Haematol. 77:
274–281.
52. Itoh, K., and N. Chiorazzi. 2000. Clonal expansion is a char-
acteristic feature of the B-cell repertoire of patients with
rheumatoid arthritis. Arthritis Res. 2:50–58.
53. Pearse, M., P. Gallagher, A. Wilson, L. Wu, N. Fisicaro, J.F.
Miller, R. Scollay, and K. Shortman. 1988. Molecular char-
acterization of T-cell antigen receptor expression by subsets
of CD42 CD82 murine thymocytes. Proc. Natl. Acad. Sci.
USA. 85:6082–6086.
54. Papavasiliou, F., R. Casellas, H. Suh, X.-F. Qin, E. Besmer,
R. Pelanda, D. Nemazee, K. Rajewsky, and M. Nussenz-
weig. 1997. V(D)J recombination in mature B cells: a mecha-
nism for altering antibody responses. Science. 278:298–300.
55. Schlissel, M., A. Constantinescu, T. Morrow, M. Baxter, and
A. Peng. 1993. Double-strand signal sequence breaks in
V(D)J recombination are blunt, 59-phosphorylated, RAG-
dependent, and cell cycle regulated. Genes Dev. 7:2520–2532.
56. Meffre, E., F. Papavasiliou, P. Cohen, O. de Bouteiller, D.
Bell, H. Karasuyama, C. Schiff, J. Banchereau, Y.J. Liu, and
M.C. Nussenzweig. 1998. Antigen receptor engagement
turns off the V(D)J recombination machinery in human tonsil
B cells. J. Exp. Med. 188:765–772.
57. Bridges, S.L., Jr., S.K. Lee, W.J. Koopman, and H.W.
Schroeder, Jr. 1993. Analysis of immunoglobulin gamma
heavy chain expression in synovial tissue of a patient with
rheumatoid arthritis. Arthritis Rheum. 36:631–641.
58. Berek, C., G.M. Griffiths, and C. Milstein. 1985. Molecular
events during maturation of the immune response to ox-
azolone.  Nature. 316:412–418.
59. Bridges, S.L., Jr., B.E. Clausen, J.C. Lavelle, P.G. Fowler,
W.J. Koopman, and H.W. Schroeder, Jr. 1995. Analysis of
immunoglobulin gamma heavy chains from rheumatoid ar-
thritis synovium. Evidence of antigen-driven selection. Ann.
NY Acad. Sci. 764:450–452.
60. Radic, M.Z., and M. Zouali. 1996. Receptor editing, im-
mune diversification, and self-tolerance. Immunity. 5:505–
511.
61. Usuda, S., T. Takemori, M. Matsuoka, T. Shirasawa, K.
Yoshida, A. Mori, K. Ishizaka, and H. Sakano. 1992. Immu-
noglobulin V gene replacement is caused by the intramolecu-
lar DNA deletion mechanism. EMBO (Eur. Mol. Biol. Or-
gan.) J. 11:611–618.
62. Conley, M.E., L. Rapalus, E.C. Boylin, J. Rohrer, and Y.
Minegishi. 1999. Gene conversion events contribute to the
polymorphic variation of the surrogate light chain gene
lambda 5/14.1. Clin. Immunol. 93:162–167.
63. Reynaud, C.A., V. Anquez, H. Grimal, and J.C. Weill. 1987.
A hyperconversion mechanism generates the chicken light
chain preimmune repertoire. Cell. 48:379–388.
64. Thompson, C.B., and P.E. Neiman. 1987. Somatic diversifi-
cation of the chicken immunoglobulin light chain gene is
limited to the rearranged variable gene segment. Cell. 48:
369–378.
65. Becker, R.S., and K.L. Knight. 1990. Somatic diversification
of immunoglobulin heavy chain VDJ genes: evidence for so-
matic gene conversion in rabbits. Cel. 63:987–997.
66. Schiaffella, E., D. Sehgal, A.O. Anderson, and R.G. Mage.
1999. Gene conversion and hypermutation during diversifi-
cation of VH sequences in developing splenic germinal cen-
ters of immunized rabbits. J. Immunol. 162:3984–3995.
67. Hesse, J.E., M.R. Lieber, K. Mizuuchi, and M. Gellert.
1989. V(D)J recombination: a functional definition of the
joining signals. Genes Dev. 3:1053–1061.
68. Bogue, M.A., C. Wang, C. Zhu, and D.B. Roth. 1997.
V(D)J recombination in Ku86-deficient mice: distinct effects
on coding, signal, and hybrid joint formation. Immunity.
7:37–47.
69. Han, J.O., S.B. Steen, and D.B. Roth. 1997. Ku86 is not re-
quired for protection of signal ends or for formation of non-
standard V(D)J recombination products. Mol. Cell. Biol. 17:
2226–2234.
70. Brezinschek, H.P., S.J. Foster, R.I. Brezinschek, T. Dorner,
R. Domiati-Saad, and P.E. Lipsky. 1997. Analysis of the hu-
man VH gene repertoire. Differential effects of selection and
somatic hypermutation on human peripheral CD51/IgM1
and CD52/IgM1 B cells. J. Clin. Invest. 99:2488–2501.
71. Komori, T., Y. Minami, N. Sakato, and H. Sugiyama. 1993.
Biased usage of two restricted VH gene segments in VH re-
placement. Eur. J. Immunol. 23:517–522.
72. Arpin, C., O. de Bouteiller, D. Razanajaona, I. Fugier-
Vivier, F. Briere, J. Banchereau, S. Lebecque, and Y.J. Liu.
1998. The normal counterpart of IgD myeloma cells in ger-
minal center displays extensively mutated IgVH gene, Cmu-
Cdelta switch, and lambda light chain expression. J. Exp.
Med. 187:1169–1178.
73. Lam, K.P., R. Kuhn, and K. Rajewsky. 1997. In vivo abla-
tion of surface immunoglobulin on mature B cells by induc-
ible gene targeting results in rapid cell death. Cell. 90:1073–
1083.
74. Meffre, E., E. Davis, C. Schiff, C. Cunningham-Rundles,
L.B. Ivashkiv, L.M. Staudt, J.W. Young, and M.C. Nussenz-
weig. 2000. Circulating human B cells that express surrogate
light chains and edited receptors. Nat. Immunol. 1:207–214.
75. Randen, I., D. Brown, K.M. Thompson, N. Hughes-Jones,
V. Pascual, K. Victor, J.D. Capra, O. Forre, and J.B. Natvig.
1992. Clonally related IgM rheumatoid factors undergo affin-
ity maturation in the rheumatoid synovial tissue. J. Immunol.
148:3296–3301.
76. Tuomi, T., K. Aho, T. Palosuo, K. Kaarela, R. von Essen,
H. Isomaki, M. Leirisalo-Repo, and S. Sarna. 1988. Signifi-
cance of rheumatoid factors in an eight-year longitudinal
study on arthritis. Rheumatol. Int. 8:21–26.
77. Munthe, E., and J.B. Natvig. 1972. Immunoglobulin classes,
subclasses and complexes of IgG rheumatoid factor in rheu-
matoid plasma cells. Clin. Exp. Immunol. 12:55–70.
78. Hertz, M., V. Kouskoff, T. Nakamura, and D. Nemazee.
1998. V(D)J recombinase induction in splenic B lymphocytes
is inhibited by antigen-receptor signalling. Nature. 394:292–
295.
79. Dorner, T., S.J. Foster, N.L. Farner, and P.E. Lipsky. 1998.
Immunoglobulin kappa chain receptor editing in systemic lu-
pus erythematosus. J. Clin. Invest. 102:688–694.
80. Chen, P.P., G.J. Silverman, M.F. Liu, and D.A. Carson.1164 VH Replacement in Synovial Tissue B Lymphocytes
1990. Idiotypic and molecular characterization of human
rheumatoid factors. Chem. Immunol. 48:63–81.
81. Jukes, T.H., and J.L. King. 1979. Evolutionary nucleotide re-
placements in DNA. Nature. 281:605–606.
82. Shlomchik, M.J., A. Marshak-Rothstein, C.B. Wolfowicz,
T.L. Rothstein, and M.G. Weigert. 1987. The role of clonal
selection and somatic mutation in autoimmunity. Nature.
328:805–811.
83. Rogozin, I.B., N.E. Sredneva, and N.A. Kolchanov. 1996.
Somatic hypermutagenesis in immunoglobulin genes. III. So-
matic mutations in the chicken light chain locus. Biochim.
Biophys. Acta. 1306:171–178.
84. Manheimer-Lory, A.J., G. Zandman-Goddard, A. Davidson,
C. Aranow, and B. Diamond. 1997. Lupus-specific antibod-
ies reveal an altered pattern of somatic mutation. J. Clin. In-
vest. 100:2538–2546.